It has been reported that high EZH2 expression is prognostic for poor clinical outcome in neuroblastoma patients and that EZH2-catalyzed H3K27me3 is responsible for transcriptional repression of several neuroblastoma tumor-suppressor genes, including CASZ1 GLU, RUNX3, and NGFR19. This evidence concerns the gene EZH2 and neoplasm.